Opportunity Information: Apply for RFA CA 14 004
Apply for RFA CA 14 004
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Dec 20, 2013 and posted on Dec 20, 2013.
- Applicants must submit their applications by Sep 18, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $4,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- The number of recipients for this funding is limited to 12 candidate(s).
- Eligible applicants include: For profit organizations other than small businesses Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Special district governments City or township governments State governments Private institutions of higher education Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses County governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity "Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33)" (Funding Opportunity Number RFA-CA-14-004) supports projects that move promising molecular and cellular analysis technologies beyond early-stage prototyping and into rigorous, cancer-relevant validation. The focus is on advanced development and technical or analytical validation in an appropriate biological system tied to cancer research needs. In practical terms, this program is meant for technologies that have already cleared proof-of-principle and the pilot development phase, have supportive preliminary data, and are ready for the kind of refinement and testing that demonstrates whether they truly work as intended in realistic, cancer-relevant settings.
A key idea in the announcement is what NIH means by an "emerging technology." Here, it is not a brand-new concept or an untested prototype; it is a method or platform that looks genuinely promising, has been shown to work in initial demonstrations, but has not yet been evaluated thoroughly in the context where it is supposed to be used. The R33 mechanism is used to push that technology toward readiness for broader adoption by establishing performance characteristics, identifying limitations, improving robustness, and demonstrating utility in systems that reflect cancer biology or clinically relevant contexts.
The program is explicitly oriented toward technologies that could accelerate progress across a wide range of cancer research areas. That includes basic cancer biology, treatment and diagnosis, early detection and screening, cancer control and epidemiology, and research aimed at understanding and reducing cancer health disparities. The technologies supported under this FOA are expected to have the potential for major impact, meaning they should be applicable to a broad area of cancer-relevant research rather than being narrowly useful for a single specialized question. The intent is that, if the project succeeds, the resulting molecular analysis technology would enable new kinds of measurements, improve accuracy or sensitivity, increase throughput, reduce costs, or otherwise meaningfully expand what researchers and clinicians can do when studying cancer.
This FOA draws a firm boundary around what is and is not responsive. Proposals are expected to center on the technology itself: its advancement, optimization, and validation. Applications that mainly use established, widely available technologies, where the primary novelty lies in the biological or clinical question being asked, are considered non-responsive. In other words, the innovation must be in the molecular or cellular analysis technology or methodology, not simply in the scientific question being explored with routine tools. The announcement states that projects falling into that category are not appropriate and will not be reviewed, which signals that applicants need to frame the work as technology development and validation rather than hypothesis-driven biology using standard methods.
From an administrative and funding perspective, this is a discretionary grant opportunity under NIH, categorized under Education and Health, and tied to several cancer-related CFDA listings: 93.393 (Cancer Cause and Prevention Research), 93.394 (Cancer Detection and Diagnosis Research), and 93.395 (Cancer Treatment Research). NIH expected to make about 12 awards, with an estimated total funding level of about $4,000,000 and an award ceiling of $300,000. There is no cost-sharing or matching requirement, which lowers the barrier for applicants that may not have significant non-federal funds to contribute.
Eligibility is broad and includes many organization types across the public, private, nonprofit, and academic sectors. Eligible applicants include for-profit organizations (other than small businesses) and small businesses, nonprofits with and without 501(c)(3) status, public and private institutions of higher education, and a wide range of government entities such as state, county, city or township governments, special district governments, independent school districts, and public or Indian housing authorities. The eligibility list also explicitly includes several categories often highlighted for inclusive participation, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander-Serving Institutions (AANAPISIs). Faith-based and community-based organizations are included, along with regional organizations, U.S. territories or possessions, and eligible federal agencies. Notably, the FOA also allows non-domestic (non-U.S.) entities (foreign organizations), which is important for technology development efforts that may be centered in international research environments.
Timing details reflect that this opportunity was posted and created on December 20, 2013, with an original and current closing date of September 18, 2014, and an archive date of October 19, 2014. Even though the specific solicitation is now archived, the summary is still useful as a template for understanding the kind of technology-focused R33 opportunity NIH periodically offers in the cancer technology space, especially the emphasis on moving from promising proof-of-concept to validated performance in cancer-relevant systems.
The full announcement was hosted on the NIH grants site (grants.nih.gov) under the RFA file path for RFA-CA-14-004, and the contact listed for access or technical problems was the NIH Office of Extramural Research (OER) Webmaster (FBOWebmaster@OD.NIH.GOV).
FAQs: NIH R33 Funding Opportunity RFA-CA-14-004
What is this funding opportunity?
This is an NIH funding opportunity titled "Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33)" under Funding Opportunity Number RFA-CA-14-004. It supports projects that advance promising molecular and cellular analysis technologies beyond early prototyping and into rigorous, cancer-relevant validation.
What does the R33 mechanism support in this announcement?
The R33 mechanism is used here to push an emerging technology from a working early demonstration toward readiness for broader adoption. The emphasis is on advanced development plus technical and/or analytical validation, including establishing performance characteristics, identifying limitations, improving robustness, and demonstrating utility in biological systems tied to cancer research needs.
What stage of technology development is expected for applicants?
The program is aimed at technologies that have already cleared proof-of-principle and pilot development. Applications are expected to include supportive preliminary data and propose refinement and testing that shows whether the technology performs as intended in realistic, cancer-relevant settings.
How does NIH define an "emerging technology" for this FOA?
In this FOA, an "emerging technology" is not a brand-new concept or an untested prototype. It is a method or platform that appears genuinely promising, has been shown to work in initial demonstrations, but has not yet been thoroughly evaluated in the context where it is intended to be used.
What kinds of projects are considered responsive to the FOA?
Projects are expected to center on the technology itself: its advancement, optimization, and validation. The work should focus on demonstrating performance and utility in an appropriate biological system tied to cancer research needs, rather than primarily using routine tools to answer a biological question.
What kinds of projects are considered non-responsive?
Applications that mainly use established, widely available technologies, where the primary novelty lies in the biological or clinical question being asked, are considered non-responsive. The innovation must be in the molecular or cellular analysis technology or methodology. The FOA states that non-responsive projects are not appropriate and will not be reviewed.
What research areas can the supported technologies impact?
The FOA is oriented toward technologies that could accelerate progress across a wide range of cancer research areas, including basic cancer biology, treatment and diagnosis, early detection and screening, cancer control and epidemiology, and work aimed at understanding and reducing cancer health disparities.
Does the FOA expect the technology to be broadly useful?
Yes. Technologies supported under this FOA are expected to have the potential for major impact and be applicable to a broad area of cancer-relevant research rather than being narrowly useful for a single specialized question.
What outcomes or improvements does NIH expect these technologies to enable?
If successful, the technology is expected to enable new kinds of measurements and/or improve capabilities such as accuracy, sensitivity, throughput, or cost. More broadly, it should meaningfully expand what researchers and clinicians can do when studying cancer.
What is the funding category and general topic area for this opportunity?
This is a discretionary NIH grant opportunity categorized under Education and Health, focused on cancer-related molecular and cellular analysis technology development and validation.
Which CFDA programs are associated with this FOA?
The FOA is tied to several cancer-related CFDA listings: 93.393 (Cancer Cause and Prevention Research), 93.394 (Cancer Detection and Diagnosis Research), and 93.395 (Cancer Treatment Research).
How many awards were expected and what was the estimated total funding?
NIH expected to make about 12 awards, with an estimated total funding level of about $4,000,000.
What is the award ceiling mentioned in the summary?
The award ceiling is listed as $300,000.
Is cost-sharing or matching required?
No. The summary states there is no cost-sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad and includes many organization types across the public, private, nonprofit, and academic sectors, including for-profit organizations (other than small businesses) and small businesses; nonprofits with and without 501(c)(3) status; public and private institutions of higher education; and many government entities (state, county, city/township, special district, independent school districts, and public or Indian housing authorities).
Are minority-serving institutions and community-based organizations included in eligibility?
Yes. The eligibility list explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American and Native American Pacific Islander-Serving Institutions (AANAPISIs), as well as faith-based and community-based organizations and regional organizations.
Are U.S. territories and federal agencies eligible?
Yes. The eligibility list includes U.S. territories or possessions and eligible federal agencies.
Are non-U.S. (foreign) organizations allowed to apply?
Yes. The FOA allows non-domestic (non-U.S.) entities (foreign organizations), which can be important for technology development efforts based in international research environments.
When was this opportunity posted and when did it close?
The opportunity was posted and created on December 20, 2013. The original and current closing date is listed as September 18, 2014.
Is this FOA still active?
No. The archive date is listed as October 19, 2014, meaning the specific solicitation is archived.
Why might this archived FOA still be useful to read?
Even though it is archived, the summary can still serve as a template for understanding the kind of technology-focused R33 opportunity NIH periodically offers in the cancer technology space, especially the emphasis on moving from proof-of-concept to validated performance in cancer-relevant systems.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants site (grants.nih.gov) under the RFA file path for RFA-CA-14-004.
Who was listed as the contact for access or technical problems?
The contact listed for access or technical problems was the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Education Health
Next opportunity: NIH Revision Awards for Creating Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER)(R01)
Previous opportunity: Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 14 004
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 14 004) also looked into and applied for these:
| Funding Opportunity |
|---|
| Using Social Media to Understand and Address Substance Use and Addiction (R01) Apply for RFA CA 14 008 Funding Number: RFA CA 14 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Using Social Media to Understand and Address Substance Use and Addiction (R21) Apply for RFA CA 14 009 Funding Number: RFA CA 14 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R01) Apply for PA 14 061 Funding Number: PA 14 061 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R21) Apply for PA 14 062 Funding Number: PA 14 062 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R03) Apply for PA 14 063 Funding Number: PA 14 063 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (U01) Apply for PAR 14 067 Funding Number: PAR 14 067 Agency: National Institutes of Health Category: Education Health Funding Amount: $700,000 |
| Centers of Excellence in Self Management Building Research Teams for the Future (P20) Apply for RFA NR 14 001 Funding Number: RFA NR 14 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Centers of Excellence in Self Management Research (P30) Apply for RFA NR 14 002 Funding Number: RFA NR 14 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $480,000 |
| Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R43/R44) Apply for RFA DA 15 001 Funding Number: RFA DA 15 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R41/R42) Apply for RFA DA 15 002 Funding Number: RFA DA 15 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development Centers of Excellence Cooperative Program (U54) Apply for RFA DA 15 003 Funding Number: RFA DA 15 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroimmune Signaling in Substance Use Disorders (R01) Apply for PA 14 084 Funding Number: PA 14 084 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroimmune Signaling and Function in Substance Use Disorders (R21) Apply for PA 14 083 Funding Number: PA 14 083 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (R01) Apply for PAR 14 085 Funding Number: PAR 14 085 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01) Apply for PAR 14 086 Funding Number: PAR 14 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (P01) Apply for PAR 14 087 Funding Number: PAR 14 087 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 005 Funding Number: RFA DA 15 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Infection of the Central Nervous System (R01) Apply for PA 14 094 Funding Number: PA 14 094 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from Central Nervous System Reservoirs (R01) Apply for PA 14 095 Funding Number: PA 14 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization Apply for RFA CA 14 002 Funding Number: RFA CA 14 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 14 004", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.